SCHEMBL370944

SCHEMBL370944

Cn1ccc(C=O)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31321036 0.86
Quinoline SCHEMBL27346816 0.79 ALDH1A1 (0.50)
SCHEMBL25816394 0.79 HDAC1 (0.42)
SCHEMBL28091306 0.78 KAT2B (0.32)
SCHEMBL11577577 0.76
SCHEMBL22708167 0.74
SCHEMBL4419350 0.74 HDAC1 (0.46)
SCHEMBL6981903 0.73 KMT2A (0.43)
Formamide SCHEMBL10967419 0.73 KEAP1 (0.39)
SCHEMBL25610512 0.73 HDAC1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120058610-A Salicyloyl hydrazine derivative containing pyrazole group with optical switching performance, preparation method and application 南京理工大学 2025-05-30 CN claimed
EP-4013755-B1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2025-01-08 EP claimed
CN-111936144-A JAK inhibitors 廖细斌 2020-11-13 CN claimed
EP-2776407-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2014-09-17 EP claimed
WO-2013070657-A1 MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-05-16 WO claimed
EP-1828175-A2 PROCESS FOR OBTAINING ENANTIOMERS OF THIENYLAZOLYLALCOXYETHANAMINES LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-09-05 EP claimed
US-7078531-B2 Process for obtaining enantiomers of thienylazolylalcoxyethanamines LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2006-07-18 US claimed
WO-2006063860-A2 PROCESS FOR OBTAINING ENANTIOMERS OF THIENYLAZOLYLALCOXYETHANAMINES LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-06-22 WO claimed
US-20060135787-A1 PROCESS FOR OBTAINING ENANTIOMERS OF THIENYLAZOLYLALCOXYETHANAMINES LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-06-22 US claimed
EP-1671968-A1 Process for obtaining enantiomers of thienylazolylalcoxyethanamines LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2006-06-21 EP claimed
EP-4745117-A1 NOVEL INDENONE DERIVATIVE AND USE THEREOF Amyloid Solution Inc. (KR) 2026-05-20 EP disclosed
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 US disclosed
US-20260098041-A1 FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS INCYTE CORPORATION (US) 2026-04-09 US disclosed
US-12577247-B2 Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist Bugworks Research, Inc. (US) 2026-03-17 US disclosed
CN-121574101-A Preparation method and application of quinazoline compound 厦门大学 2026-02-27 CN disclosed
EP-1324985-A4 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 2004-10-06 EP disclosed
WO-2004058702-A2 4-[(4-(CARBOXYETHYL) PIPERIDINYL) METHYL] PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2004-07-15 WO disclosed
WO-2004058763-A1 4(SPIROPIPERIDINYL)METHYL SUBSTITUTED PYRROLIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2004-07-15 WO disclosed
EP-1324985-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 2003-07-09 EP disclosed
WO-2002028831-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2002-04-11 WO disclosed